

## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents  
United States Patent and Trademark  
Office  
Box PCT  
Washington, D.C.20231  
ÉTATS-UNIS D'AMÉRIQUE

in its capacity as elected Office

Date of mailing: 09 December 1999 (09.12.99)	
International application No.: PCT/AU99/00424	Applicant's or agent's file reference: 85148
International filing date: 02 June 1999 (02.06.99)	Priority date: 02 June 1998 (02.06.98)
Applicant: RYLATT, Dennis, Brian	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International preliminary Examining Authority on:  
20 October 1999 (20.10.99)☐ in a notice effecting later election filed with the International Bureau on:  
\_\_\_\_\_2. The election ☒ was☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer:  J. Zahra Telephone No.: (41-22) 338.83.38
---	---


## PATENT COOPERATION TREATY

PCT

NOTIFICATION OF THE RECORDING  
OF A CHANGE(PCT Rule 92bis.1 and  
Administrative Instructions, Section 422)

From the INTERNATIONAL BUREAU

To:

F.B. RICE & CO.  
605 Darling Street  
Balmain, NSW 2041  
AUSTRALIE

Date of mailing (day/month/year) 04 April 2000 (04.04.00)	<b>IMPORTANT NOTIFICATION</b>
Applicant's or agent's file reference 85148	
International application No. PCT/AU99/00424	International filing date (day/month/year) 02 June 1999 (02.06.99)

## 1. The following indications appeared on record concerning:

☒ the applicant      ☒ the inventor      ☐ the agent      ☐ the common representative

Name and Address	State of Nationality	State of Residence
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	

## 2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☒ the person      ☒ the name      ☒ the address      ☒ the nationality      ☒ the residence

Name and Address LIM, Sharon 28/61-89 Buckingham Street Surry Hills, NSW 2010 Australia	State of Nationality AU	State of Residence AU
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	

## 3. Further observations, if necessary:

**Added inventor and applicant for the purposes of the US only.**

## 4. A copy of this notification has been sent to:


<input checked="" type="checkbox"/> the receiving Office	<input type="checkbox"/> the designated Offices concerned
<input type="checkbox"/> the International Searching Authority	<input checked="" type="checkbox"/> the elected Offices concerned
<input checked="" type="checkbox"/> the International Preliminary Examining Authority	<input type="checkbox"/> other:

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland  Facsimile No.: (41-22) 740.14.35	Authorized officer <i>Dorothee Mülhausen</i> Dorothee Mülhausen  Telephone No.: (41-22) 338.83.38
---	--

**PATENT COOPERATION TREATY**  
**PCT**  
**INTERNATIONAL PRELIMINARY EXAMINATION REPORT**  
(PCT Article 36 and Rule 70)

Applicant's or agent's file reference <b>85148</b>	<b>FOR FURTHER ACTION</b>	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416).
International application No. <b>PCT/AU99/00424</b>	International filing date ( <i>day/month/year</i> ) <b>2 June 1999</b>	Priority Date ( <i>day/month/year</i> ) <b>2 June 1998</b>
International Patent Classification (IPC) or national classification and IPC  <b>Int. Cl. <sup>7</sup> C07K 001/26</b>		
Applicant <b>GRADIPORE LIMITED et al</b>		

1.	This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.																								
2.	This REPORT consists of a total of <b>4</b> sheets, including this cover sheet.  <input checked="" type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).  These annexes consist of a total of <b>8</b> sheet(s).																								
3.	This report contains indications relating to the following items:  <table style="width: 100%; border: none;"> <tr> <td style="width: 5%;">I</td> <td style="width: 5%;"><input checked="" type="checkbox"/></td> <td>Basis of the report</td> </tr> <tr> <td>II</td> <td><input type="checkbox"/></td> <td>Priority</td> </tr> <tr> <td>III</td> <td><input type="checkbox"/></td> <td>Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</td> </tr> <tr> <td>IV</td> <td><input type="checkbox"/></td> <td>Lack of unity of invention</td> </tr> <tr> <td>V</td> <td><input checked="" type="checkbox"/></td> <td>Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</td> </tr> <tr> <td>VI</td> <td><input type="checkbox"/></td> <td>Certain documents cited</td> </tr> <tr> <td>VII</td> <td><input type="checkbox"/></td> <td>Certain defects in the international application</td> </tr> <tr> <td>VIII</td> <td><input type="checkbox"/></td> <td>Certain observations on the international application</td> </tr> </table>	I	<input checked="" type="checkbox"/>	Basis of the report	II	<input type="checkbox"/>	Priority	III	<input type="checkbox"/>	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability	IV	<input type="checkbox"/>	Lack of unity of invention	V	<input checked="" type="checkbox"/>	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement	VI	<input type="checkbox"/>	Certain documents cited	VII	<input type="checkbox"/>	Certain defects in the international application	VIII	<input type="checkbox"/>	Certain observations on the international application
I	<input checked="" type="checkbox"/>	Basis of the report																							
II	<input type="checkbox"/>	Priority																							
III	<input type="checkbox"/>	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability																							
IV	<input type="checkbox"/>	Lack of unity of invention																							
V	<input checked="" type="checkbox"/>	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement																							
VI	<input type="checkbox"/>	Certain documents cited																							
VII	<input type="checkbox"/>	Certain defects in the international application																							
VIII	<input type="checkbox"/>	Certain observations on the international application																							

Date of submission of the demand <b>20 October 1999</b>	Date of completion of the report <b>14 August 2000</b>
Name and mailing address of the IPEA/AU  <b>AUSTRALIAN PATENT OFFICE</b> <b>PO BOX 200, WODEN ACT 2606, AUSTRALIA</b> E-mail address: <b>pct@ipaustalia.gov.au</b> Facsimile No. <b>(02) 6285 3929</b>	Authorized Officer   <b>IAN DOWD</b>  Telephone No. <b>(02) 6283 2273</b>

**I. Basis of the report****1. With regard to the elements of the international application:\***

- ☐ the international application as originally filed.
- ☒ the description, pages 5-11, 13, as originally filed,  
pages , filed with the demand,  
pages 1-4, 12, received on 27 June 2000 with the letter of 27 June 2000
- ☒ the claims, pages , as originally filed,  
pages , as amended (together with any statement) under Article 19,  
pages , filed with the demand,  
pages 14-16, received on 27 June 2000 with the letter of 27 June 2000
- ☒ the drawings, pages 1-3, as originally filed,  
pages , filed with the demand,  
pages , received on with the letter of
- ☐ the sequence listing part of the description:  
pages , as originally filed  
pages , filed with the demand  
pages , received on with the letter of

**2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.**

These elements were available or furnished to this Authority in the following language which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

**3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, was on the basis of the sequence listing:**

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

**4. ☐ The amendments have resulted in the cancellation of:**

- ☐ the description, pages
- ☐ the claims, Nos.
- ☐ the drawings, sheets/fig.

**5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).\*\***

\* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

\*\* Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement****1. Statement**

Novelty (N)	Claims 1-17	YES
	Claims nil	NO
Inventive step (IS)	Claims 1-17	YES
	Claims nil	NO
Industrial applicability (IA)	Claims 1-17	YES
	Claims nil	NO

**2. Citations and explanations (Rule 70.7)****Citations**

- Journal of Chromatography A, 827 (1998) 329-335  
"Purification of monoclonal antibodies from ascitic fluid using preparative electrophoresis"; S Lim et al
- Electrophoresis, (1994), Vol.15 (7), pages 968-971  
"Multifunctional apparatus for electrokinetic processing of proteins"; Z. Stephen Horvath et al
- Electrophoresis, (1995), Vol.16 (1), pages 98-100  
"Preparative reflux electrophoresis"; Joel Margolis et al

**NOVELTY and INVENTIVE STEP**

Document (1) was published after the priority date of the claims and before publication thereof. Upon perusal of the priority document, the claims are entitled to the priority date claimed. Therefore document (1) is excluded for the purposes of novelty and inventive step.

Document (2) discloses at Figure 1(a) a charge based electrophoretic separation of a target protein using known pH and differences in isoelectric points between contaminants and the protein. D2 exemplifies the separation of Hb (haemoglobin) from BSA (bovine serum albumin) as a specific separation to illustrate the separation effectiveness. Additionally, purification of phycoerythrin was effected with a yield over 85%. However, no specific disclosure of purifying antibodies is made in the citation, nor specific conditions for its purification, such as buffer and electrophoretic membrane characteristics. Therefore, the claims are considered to be novel in the light of D2.

With regard to inventive step, it is clearly not envisaged that the apparatus or method is solely for Hb or BSA. (See particularly page 968, column 2, lines 8-11). See also page 970, column 2 where various plant and mammalian proteins have been fractionated, and page 971, column 1 where it is clearly stated it is suitable for use in a wide range of macromolecules. A person skilled in the art faced with the problem of purifying an antibody would consider the process of the prior art as an obvious choice. However, the process of the present application produces antibodies that are less denatured than those obtained from methods of the prior art. Therefore, the process of the present application contains an advantage over that of the prior art and therefore enjoys an inventive step.

Continued on supplemental sheet

**Supplemental Box V**

(To be used when the space in any of the preceding boxes is not sufficient)

**Continuation of**

Document (3) discloses "reflux electrophoresis" where the electric potential across the membrane is periodically stopped and reversed so as to clear the membrane.

Combining Document (2) with Document (3), as would be obvious to a person skilled in the art, results in the specific disclosure of the optional periodic stopping and reversal of the electric potential across the membrane to cause backward movement of the antibody out of the membrane. However, since Document (2) is novel and inventive, and the features disclosed in Document (3) relate to optional features of the application, Document (3) does not deny the application of novelty or inventive step.

**INDUSTRIAL APPLICABILITY**

The claims relate to a method of separation that has use in the biotechnology industry. Therefore the claims have industrial applicability.

**PATENT COOPERATION TREATY**  
**PCT**  
**INTERNATIONAL PRELIMINARY EXAMINATION REPORT**  
(PCT Article 36 and Rule 70)


REC'D 19 SEP 2000

PCT

15

Applicant's or agent's file reference 85148	<b>FOR FURTHER ACTION</b>	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416).
International application No. <b>PCT/AU99/00424</b>	International filing date ( <i>day/month/year</i> ) 2 June 1999	Priority Date ( <i>day/month/year</i> ) 2 June 1998
International Patent Classification (IPC) or national classification and IPC  <b>Int. Cl. <sup>7</sup> C07K 001/26</b>		
Applicant <b>GRADIPORE LIMITED et al</b>		

1.	This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.	
2.	This REPORT consists of a total of 4 sheets, including this cover sheet.	
	<input checked="" type="checkbox"/>	This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).
These annexes consist of a total of 8 sheet(s).		
3.	This report contains indications relating to the following items:	
I	<input checked="" type="checkbox"/>	Basis of the report
II	<input type="checkbox"/>	Priority
III	<input type="checkbox"/>	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
IV	<input type="checkbox"/>	Lack of unity of invention
V	<input checked="" type="checkbox"/>	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
VI	<input type="checkbox"/>	Certain documents cited
VII	<input type="checkbox"/>	Certain defects in the international application
VIII	<input type="checkbox"/>	Certain observations on the international application

Date of submission of the demand 20 October 1999	Date of completion of the report 14 August 2000
Name and mailing address of the IPEA/AU  AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustalia.gov.au Facsimile No. (02) 6285 3929	Authorized Officer   <b>IAN DOWD</b>  Telephone No. (02) 6283 2273

**I Basis of the report**

1. With regard to the elements of the international application:\*
- ☐ the international application as originally filed.
- ☒ the description, pages 5-11, 13, as originally filed,  
pages , filed with the demand,  
pages 1-4, 12, received on 27 June 2000 with the letter of 27 June 2000
- ☒ the claims, pages , as originally filed,  
pages , as amended (together with any statement) under Article 19,  
pages , filed with the demand,  
pages 14-16, received on 27 June 2000 with the letter of 27 June 2000
- ☒ the drawings, pages 1-3, as originally filed,  
pages , filed with the demand,  
pages , received on with the letter of
- ☐ the sequence listing part of the description:  
pages , as originally filed  
pages , filed with the demand  
pages , received on with the letter of
2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.  
These elements were available or furnished to this Authority in the following language which is:
- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).
3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, was on the basis of the sequence listing:
- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished
4. ☐ The amendments have resulted in the cancellation of:
- ☐ the description, pages
- ☐ the claims, Nos.
- ☐ the drawings, sheets/fig.
5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).\*\*

\* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

\*\* Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report



**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement****1. Statement**

Novelty (N)	Claims 1-17	YES
	Claims nil	NO
Inventive step (IS)	Claims 1-17	YES
	Claims nil	NO
Industrial applicability (IA)	Claims 1-17	YES
	Claims nil	NO

**2. Citations and explanations (Rule 70.7)****Citations**

- Journal of Chromatography A, 827 (1998) 329-335  
"Purification of monoclonal antibodies from ascitic fluid using preparative electrophoresis"; S Lim et al
- Electrophoresis, (1994), Vol.15 (7), pages 968-971  
"Multifunctional apparatus for electrokinetic processing of proteins"; Z. Stephen Horvath et al
- Electrophoresis, (1995), Vol.16 (1), pages 98-100  
"Preparative reflux electrophoresis"; Joel Margolis et al

**NOVELTY and INVENTIVE STEP**

Document (1) was published after the priority date of the claims and before publication thereof. Upon perusal of the priority document, the claims are entitled to the priority date claimed. Therefore document (1) is excluded for the purposes of novelty and inventive step.

Document (2) discloses at Figure 1(a) a charge based electrophoretic separation of a target protein using known pH and differences in isoelectric points between contaminants and the protein. D2 exemplifies the separation of Hb (haemoglobin) from BSA (bovine serum albumin) as a specific separation to illustrate the separation effectiveness. Additionally, purification of phycoerythrin was effected with a yield over 85%. However, no specific disclosure of purifying antibodies is made in the citation, nor specific conditions for its purification, such as buffer and electrophoretic membrane characteristics. Therefore, the claims are considered to be novel in the light of D2.

With regard to inventive step, it is clearly not envisaged that the apparatus or method is solely for Hb or BSA. (See particularly page 968, column 2, lines 8-11). See also page 970, column 2 where various plant and mammalian proteins have been fractionated, and page 971, column 1 where it is clearly stated it is suitable for use in a wide range of macromolecules. A person skilled in the art faced with the problem of purifying an antibody would consider the process of the prior art as an obvious choice. However, the process of the present application produces antibodies that are less denatured than those obtained from methods of the prior art. Therefore, the process of the present application contains an advantage over that of the prior art and therefore enjoys an inventive step.

Continued on supplemental sheet

**Supplemental Box V**

(To be used when the space in any of the preceding boxes is not sufficient)

**Continuation of**

Document (3) discloses "reflux electrophoresis" where the electric potential across the membrane is periodically stopped and reversed so as to clear the membrane.

Combining Document (2) with Document (3), as would be obvious to a person skilled in the art, results in the specific disclosure of the optional periodic stopping and reversal of the electric potential across the membrane to cause backward movement of the antibody out of the membrane. However, since Document (2) is novel and inventive, and the features disclosed in Document (3) relate to optional features of the application, Document (3) does not deny the application of novelty or inventive step.

**INDUSTRIAL APPLICABILITY**

The claims relate to a method of separation that has use in the biotechnology industry. Therefore the claims have industrial applicability.

## CLAIMS:

1. A method of separation of an antibody from a mixture of the antibody and at least one contaminant, the method comprising:

(a) placing the antibody and contaminant mixture in a first solvent stream, the first solvent stream being separated from a second solvent stream by an electrophoretic membrane;

(b) selecting a pH for the first solvent stream such that contaminants with an isoelectric point (pI) lower than the antibody to be separated will be charged;

(c) applying an electric potential between the two solvent streams causing movement of at least some of the contaminants through the membrane into the second solvent stream while the antibody is substantially retained in the first solvent stream, or if entering the membrane, being substantially prevented from entering the second solvent stream;

(d) optionally, periodically stopping and reversing the electric potential to cause movement of any antibody having entered the membrane to move back into the first solvent stream, wherein substantially not causing any contaminants that have entered the second solvent stream to re-enter first solvent stream; and

(e) repeating step (c) and optionally step (d) until the first solvent stream contains the desired purity of antibody.

2. The method according to claim 1 wherein the antibody and contaminant mixture is a monoclonal antibody in ascitic fluid.

3. The method according to claim 1 or 2 wherein the electrophoretic membrane has a molecular mass cut-off of 50 to 150 kDa.

4. The method according to claim 3 wherein the electrophoretic membrane has a molecular mass cut-off of 100 kDa.

5. The method according to any one of claims 1 to 4 wherein the pH of the first solvent stream is 7.5 to 9.5.

6. The method according to any one of claims 1 to 5 further including the steps of:

(f) placing the separated antibody in a fresh first solvent stream, the first solvent stream being separated from a second solvent stream by an electrophoretic membrane;

(g) selecting a pH of the fresh first solvent stream such that the pH is within 1 pH unit of the pI of the antibody;

REPLACED BY  
ART 34 AMDT

- (h) applying an electric potential between the two solvent streams causing movement of at least some of the contaminants through the membrane into the second solvent stream while the antibody is substantially retained in the fresh first solvent stream, or if entering the membrane, being substantially prevented from entering the second solvent stream;
- (i) optionally, periodically stopping and reversing the electric potential to cause movement of any antibody having entered the membrane to move back into the fresh first solvent stream, wherein substantially not causing any contaminants that have entered the second solvent stream to re-enter fresh first solvent stream; and
- (j) repeating step (h) and optionally step (i) until the fresh first solvent stream contains the desired purity of antibody.
7. The method according to claim 6 wherein the molecular mass cut-off of the membrane used in step (f) is larger than that used in step (b).
8. The method according to claim 7 wherein the molecular mass cut-off of the electrophoretic membrane used in step (f) is at least 200 kDa.
9. The method according to claim 8 wherein the molecular mass cut-off of the electrophoretic membrane used in step (f) is 1000 kDa.
10. The method according to any one of claims 6 to 9 wherein the pH in step (g) is from 6 to 8.
11. The method according any one of claims 6 to 9 wherein the pH in step (g) is within 0.5 pH units of the *pI* of the antibody.
12. The method according to any one of claims 1 to 11 wherein percent recovery of the antibody is at least 70%.
13. The method according to claim 12 wherein percent recovery of the antibody is at least 90%.
14. A method of separation of an antibody from a mixture of the antibody and at least one contaminant, the method comprising:
- (a) placing the separated antibody in a first solvent stream, the first solvent stream being separated from a second solvent stream by an electrophoretic membrane;
- (b) selecting a pH of the first solvent stream such that the pH is within 1 pH unit of the *pI* of the antibody;
- (c) applying an electric potential between the two solvent streams causing movement of at least some of the contaminants through the membrane into the second solvent stream while the antibody is substantially retained in the

REPLACED BY  
ART 34 AMDT

first solvent stream, or if entering the membrane, being substantially prevented from entering the second solvent stream;

(d) optionally, periodically stopping and reversing the electric potential to cause movement of any antibody having entered the membrane to move back into the first solvent stream, wherein substantially not causing any contaminants that have entered the second solvent stream to re-enter first solvent stream; and

(e) repeating step (c) and optionally step (d) until the first solvent stream contains the desired purity of antibody.

15. The method according to claim 14 wherein the antibody and contaminant mixture is a monoclonal antibody in ascitic fluid.

16. The method according to claim 14 or 15 wherein the molecular mass cut-off of the electrophoretic membrane used in step (a) is at least 200 kDa.

17. The method according to claim 16 wherein the molecular mass cut-off of the electrophoretic membrane used in step (a) is 1000 kDa.

18. The method according to any one of claims 14 to 17 wherein the pH in step (b) is from 6 to 8.

19. The method according to any one of claims 14 to 17 wherein the pH in step (b) is within 0.5 pH units of the pI of the antibody.

20. An antibody purified by the method according to any one of claims 1 to 19.

21. The antibody according to claim 20 being a monoclonal antibody.

REPLACED BY  
ART 34 AMDT

Table 3. Yield of Rat IgG2b monoclonal antibody

Purification Method	Yield (%)
Protein-G	83
Invention	91
Ion exchange	81

5 Electrophoretic analysis (SDS-PAGE) of antibodies purified by the present invention revealed lower number of protein bands indicating that the present method does not cleave or damage the antibodies compared with other purification techniques. Not only can the present invention provide greater yields of antibody, the invention also provides more active and less denatured antibody preparations.

10 It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

REPLACED BY  
ART 34 AMDT

Purification of AntibodiesTechnical Field

The present invention relates to methods suitable for purification of antibodies, particularly monoclonal antibodies from ascites fluid.

5 Background Art

The processing of complex biological solutions is a major bottleneck in the biotechnology industry and there is a strong demand for cost effective technologies for the purification of naturally occurring and recombinant proteins. This is particularly true for antibodies including monoclonal antibodies, where there has been an on-going search for simple generic methods of purification. In particular, monoclonal antibodies have had an increasing number of research, therapeutic and diagnostic applications since their initial production in 1975. The difficulties in bioprocessing have meant that recoveries of monoclonal antibodies in existing purification schemes are rarely reported but are often in the range of 10 to 70%. Although new processes have become increasingly effective in terms of yield and recovery, commonly used processes often utilise harsh pH or ionic strength conditions for elution which may not always be compatible with maintaining maximal biological activity of antibodies.

20 The present inventor has found that preparative electrophoresis using Gradiflow technology (AU 601040) is particularly suitable for the purification of antibodies. In contrast to conventional methods, Gradiflow uses mild, non-denaturing buffers and conditions which may be utilised to produce more active antibody preparations.

25 Disclosure of Invention

In a first aspect, the present invention consists in a method of separation of an antibody from a mixture of the antibody and at least one contaminant, the method comprising:

- 30 (a) placing the antibody and contaminant mixture in a first solvent stream, the first solvent stream being separated from a second solvent stream by an electrophoretic membrane;
- (b) selecting a pH for the first solvent stream such that contaminants with an isoelectric point (pI) lower than the antibody to be separated will be charged;
- 35 (c) applying an electric potential between the two solvent streams causing movement of at least some of the contaminants through the membrane into

REPLACED BY  
ART 34 AMDT

the second solvent stream while the antibody is substantially retained in the first solvent stream, or if entering the membrane, being substantially prevented from entering the second solvent stream;

5 (d) optionally, periodically stopping and reversing the electric potential to cause movement of any antibody having entered the membrane to move back into the first solvent stream, wherein substantially not causing any contaminants that have entered the second solvent stream to re-enter first solvent stream: and

10 (e) repeating step (c) and optionally step (d) until the first solvent stream contains the desired purity of antibody.

Preferably, the antibody and contaminant mixture is a monoclonal antibody in ascitic fluid.

15 In a preferred embodiment of the first aspect of the present invention, the electrophoretic membrane has a molecular mass cut-off of about 50 to 150 kDa, preferably about 100 kDa. The *pI* of the antibody to be separated is usually obtained by isoelectric focusing (IEF). The pH of the first solvent stream is preferably about 7.5 to 9.5. Major protein contaminants, including albumin whose *pI* is well known to be 4.9, can be separated from the antibodies by being caused to transfer into the second solvent stream at pH  
20 8.3.

In a second aspect, the present invention consists in a method of separation of an antibody from a mixture of the antibody and at least one contaminant, the method comprising:

25 (a) placing the separated antibody in a first solvent stream, the first solvent stream being separated from a second solvent stream by an electrophoretic membrane;

(b) selecting a pH of the first solvent stream such that the pH is within 1 pH unit of the *pI* of the antibody;

30 (c) applying an electric potential between the two solvent streams causing movement of at least some of the contaminants through the membrane into the second solvent stream while the antibody is substantially retained in the first solvent stream, or if entering the membrane, being substantially prevented from entering the second solvent stream;

35 (d) optionally, periodically stopping and reversing the electric potential to cause movement of any antibody having entered the membrane to move back into the first solvent stream, wherein substantially not causing any

REPLACED BY  
ART 34/1977



contaminants that have entered the second solvent stream to re-enter first solvent stream; and

(e) repeating step (c) and optionally step (d) until the first solvent stream contains the desired purity of antibody.

5 The electrophoretic membrane in step (a) preferably has a molecular mass cut-off at least about 200 kDa to ensure the contaminants can pass through to the second solvent stream. A cartridge containing a large 1000 kDa pore size separating-membrane has been found to be particularly suitable for this aspect of the present invention. The pH in step (b) is typically from about 6 to 8.0. It will be appreciated that the pH of the buffer will depend on the pI of the antibody to be purified and the pIs of the contaminants.

10 The pH of the buffer used in step (b) can be above or below the pI of the antibody to be separated. Preferably, the pH is within 0.5 pH units of the pI of the antibody.

In a third aspect, the present invention consists in a method of separation of an antibody from a mixture of the antibody and at least one contaminant, the method comprising:

20 (a - e) separating the antibody according to the first aspect of the present invention;

(f) placing the separated antibody in a fresh first solvent stream, the first solvent stream being separated from a second solvent stream by an electrophoretic membrane;

25 (g) selecting a pH of the fresh first solvent stream such that the pH is within 1 pH unit of the pI of the antibody;

30 (h) applying an electric potential between the two solvent streams causing movement of at least some of the contaminants through the membrane into the second solvent stream while the antibody is substantially retained in the fresh first solvent stream, or if entering the membrane, being substantially prevented from entering the second solvent stream;

35 (i) optionally, periodically stopping and reversing the electric potential to cause movement of any antibody having entered the membrane to move back into the fresh first solvent stream, wherein substantially not causing any contaminants that have entered the second solvent stream to re-enter first solvent stream; and

(j) repeating step (h) and optionally step (i) until the fresh first solvent stream contains the desired purity of antibody.

The molecular mass cut-off of the electrophoretic membrane used in step (f) is preferably larger than the membrane used in step (b). The electrophoretic membrane in step (f) preferably has a molecular mass cut-off at least about 200 kDa to ensure the contaminants can pass through to the second solvent stream. A cartridge containing a large 1000 kDa pore size separating-membrane has been found to be particularly suitable for this aspect of the present invention. The pH in step (g) is typically from about 6 to 8.0. It will be appreciated that the pH of the buffer will depend on the pI of the antibody to be purified and the pIs of the contaminants.

The pH of the buffer used in step (g) can be above or below the pI of the antibody to be separated. Preferably, the pH is within 0.5 pH units of the pI of the antibody.

The present inventor has been able to obtain percent recoveries of monoclonal antibodies from ascitic fluid of at least 70% and often greater than 90% using the methods according to the present invention.

In a fourth aspect, the present invention consists in use of Gradiflow in the purification and/or separation of antibodies.

In a fifth aspect, the present invention consists in an antibody purified by the method according to the first, second or third aspects of the present invention.

Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

In order that the present invention may be more clearly understood, preferred forms will be described in the following examples with reference to the accompanying drawings.

#### Brief Description of Drawings

Figure 1 shows the operating modes of the Gradiflow separating cartridge. (a) Sized-based separation - this is a first step in which major contaminants are removed downstream from antibody mixture upstream.

(b) Charge-based separation - this is a second step suitable to remove any residual contaminants if requiring antibodies of higher purity.

REPLACED BY  
ART 34 AMDT

## Purification of Antibodies

### Technical Field

The present invention relates to methods suitable for purification of antibodies, particularly monoclonal antibodies from ascites fluid.

### 5 Background Art

The processing of complex biological solutions is a major bottleneck in the biotechnology industry and there is a strong demand for cost effective technologies for the purification of naturally occurring and recombinant proteins. This is particularly true for antibodies including monoclonal  
10 antibodies, where there has been an on-going search for simple generic methods of purification. In particular, monoclonal antibodies have had an increasing number of research, therapeutic and diagnostic applications since their initial production in 1975. The difficulties in bioprocessing have meant that recoveries of monoclonal antibodies in existing purification schemes are  
15 rarely reported but are often in the range of 10 to 70%. Although new processes have become increasingly effective in terms of yield and recovery, commonly used processes often utilise harsh pH or ionic strength conditions for elution which may not always be compatible with maintaining maximal biological activity of antibodies.

20 The present inventor has found that preparative electrophoresis using Gradiflow technology (AU 601040) is particularly suitable for the purification of antibodies. In contrast to conventional methods, Gradiflow uses mild, non-denaturing buffers and conditions which may be utilised to produce more active antibody preparations.

### 25 Disclosure of Invention

In a first aspect, the present invention consists in a method of separation of an antibody from a mixture of the antibody and at least one contaminant, the method comprising:

- (a) placing the antibody and contaminant mixture in a first solvent stream,  
30 the first solvent stream being separated from a second solvent stream by an electrophoretic membrane;
- (b) selecting a pH for the first solvent stream such that contaminants with an isoelectric point (pI) lower than the antibody to be separated will be charged;
- 35 (c) applying an electric potential between the two solvent streams causing movement of at least some of the contaminants through the membrane into

the second solvent stream while the antibody is substantially retained in the first solvent stream, or if entering the membrane, being substantially prevented from entering the second solvent stream;

(d) optionally, periodically stopping and reversing the electric potential to cause movement of any antibody having entered the membrane to move back into the first solvent stream, wherein substantially not causing any contaminants that have entered the second solvent stream to re-enter first solvent stream; and

(e) repeating step (c) and optionally step (d) until the first solvent stream contains the desired purity of antibody.

Preferably, the antibody and contaminant mixture is a monoclonal antibody in ascitic fluid.

In a preferred embodiment of the first aspect of the present invention, the electrophoretic membrane has a molecular mass cut-off of about 50 to 150 kDa, preferably about 100 kDa. The *pI* of the antibody to be separated is usually obtained by isoelectric focusing (IEF). The pH of the first solvent stream is preferably about 7.5 to 9.5. Major protein contaminants, including albumin whose *pI* is well known to be 4.9, can be separated from the antibodies by being caused to transfer into the second solvent stream at pH 8.3.

In a second aspect, the present invention consists in a method of separation of an antibody from a mixture of the antibody and at least one contaminant, the method comprising:

(a) placing the separated antibody in a first solvent stream, the first solvent stream being separated from a second solvent stream by an electrophoretic membrane;

(b) selecting a pH of the first solvent stream such that the pH is within 1 pH unit of the *pI* of the antibody;

(c) applying an electric potential between the two solvent streams causing movement of at least some of the contaminants through the membrane into the second solvent stream while the antibody is substantially retained in the first solvent stream, or if entering the membrane, being substantially prevented from entering the second solvent stream;

(d) optionally, periodically stopping and reversing the electric potential to cause movement of any antibody having entered the membrane to move back into the first solvent stream, wherein substantially not causing any

contaminants that have entered the second solvent stream to re-enter first solvent stream; and

(e) repeating step (c) and optionally step (d) until the first solvent stream contains the desired purity of antibody.

5           The electrophoretic membrane in step (a) preferably has a molecular mass cut-off at least about 200 kDa to ensure the contaminants can pass through to the second solvent stream. A cartridge containing a large 1000 kDa pore size separating-membrane has been found to be particularly suitable for this aspect of the present invention. The pH in step (b) is  
10 typically from about 6 to 8.0. It will be appreciated that the pH of the buffer will depend on the pI of the antibody to be purified and the pIs of the contaminants.

          The pH of the buffer used in step (b) can be above or below the pI of the antibody to be separated. Preferably, the pH is within 0.5 pH units of the  
15 pI of the antibody.

          In a third aspect, the present invention consists in a method of separation of an antibody from a mixture of the antibody and at least one contaminant, the method comprising:

20 (a - e) separating the antibody according to the first aspect of the present invention;

(f) placing the separated antibody in a fresh first solvent stream, the first solvent stream being separated from a second solvent stream by an electrophoretic membrane;

25 (g) selecting a pH of the fresh first solvent stream such that the pH is within 1 pH unit of the pI of the antibody;

(h) applying an electric potential between the two solvent streams causing movement of at least some of the contaminants through the membrane into the second solvent stream while the antibody is substantially retained in the fresh first solvent stream, or if entering the membrane, being substantially  
30 prevented from entering the second solvent stream;

(i) optionally, periodically stopping and reversing the electric potential to cause movement of any antibody having entered the membrane to move back into the fresh first solvent stream, wherein substantially not causing any contaminants that have entered the second solvent stream to re-enter first  
35 solvent stream; and

(j) repeating step (h) and optionally step (i) until the fresh first solvent stream contains the desired purity of antibody.

The molecular mass cut-off of the electrophoretic membrane used in step (f) is preferably larger than the membrane used in step (b). The electrophoretic membrane in step (f) preferably has a molecular mass cut-off at least about 200 kDa to ensure the contaminants can pass through to the second solvent stream. A cartridge containing a large 1000 kDa pore size separating-membrane has been found to be particularly suitable for this aspect of the present invention. The pH in step (g) is typically from about 6 to 8.0. It will be appreciated that the pH of the buffer will depend on the  $pI$  of the antibody to be purified and the  $pI$ s of the contaminants.

The pH of the buffer used in step (g) can be above or below the  $pI$  of the antibody to be separated. Preferably, the pH is within 0.5 pH units of the  $pI$  of the antibody.

The present inventors have been able to obtain percent recoveries of monoclonal antibodies from ascitic fluid of at least 70% and often greater than 90% using the methods according to the present invention.

A significant advantage of the present invention is that the separated antibody is less denatured or altered compared with the same antibody obtained by conventional antibody purification methods such as salt precipitation, Protein-A, Protein-G and ion-exchange chromatography.

In a fourth aspect, the present invention consists in use of Gradiflow in the purification and/or separation of antibodies.

In a fifth aspect, the present invention consists in an antibody purified by the method according to the first, second or third aspects of the present invention.

In order that the present invention may be more clearly understood, preferred forms will be described in the following examples with reference to the accompanying drawings.

#### Brief Description of Drawings

Figure 1 shows the operating modes of the Gradiflow separating cartridge. (a) Sized-based separation - this is a first step in which major contaminants are removed downstream from antibody mixture upstream. (b) Charge-based separation - this is a second step suitable to remove any residual contaminants if requiring antibodies of higher purity.

Table 3. Yield of Rat IgG2b monoclonal antibody

Purification Method	Yield (%)
Protein-G	83
Invention	91
Ion exchange	81

5 Electrophoretic analysis (SDS-PAGE) of antibodies purified by the  
present invention revealed lower number of protein bands indicating that the  
present method does not cleave or damage the antibodies compared with  
other purification techniques. Not only can the present invention provide  
greater yields of antibody, the invention also provides more active and less  
denatured antibody preparations.

10 Throughout this specification, unless the context requires otherwise,  
the word "comprise", or variations such as "comprises" or "comprising", will  
be understood to imply the inclusion of a stated element, integer or step, or  
group of elements, integers or steps, but not the exclusion of any other  
element, integer or step, or group of elements, integers or steps.

15 It will be appreciated by persons skilled in the art that numerous  
variations and/or modifications may be made to the invention as shown in  
the specific embodiments without departing from the spirit or scope of the  
invention as broadly described. The present embodiments are, therefore, to  
be considered in all respects as illustrative and not restrictive.

CLAIMS:

1. A method of separating an antibody from a mixture of antibody and at least one contaminant, the method comprising:
  - (a) placing the antibody and contaminant mixture in a first solvent stream, the first solvent stream being separated from a second solvent stream by an electrophoretic membrane having a molecular mass cut-off of 50 to 150 kDa;
  - (b) selecting a pH of 7.5 to 9.5 for the first solvent stream such that contaminants with an isoelectric point (pI) lower than the antibody to be separated will be charged;
  - (c) applying an electric potential between the two solvent streams causing movement of at least some of the contaminants through the membrane into the second solvent stream while the antibody is substantially retained in the first solvent stream, or if entering the membrane, being substantially prevented from entering the second solvent stream;
  - (d) optionally, periodically stopping and reversing the electric potential to cause movement of any antibody having entered the membrane to move back into the first solvent stream, wherein substantially not causing any contaminants that have entered the second solvent stream to re-enter the first solvent stream; and
  - (e) repeating step (c) and optionally step (d) until the first solvent stream contains the desired purity of antibody, wherein the recovery of the antibody is at least 70% and the antibody being less denatured or altered compared with the same antibody obtained by conventional antibody purification methods.
2. The method according to claim 1 wherein the antibody and contaminant mixture is a monoclonal antibody in ascitic fluid.
3. The method according to claim 1 or 2 wherein the electrophoretic membrane has a molecular mass cut-off of 100 kDa.
4. The method according to any one of claims 1 to 3 further including the steps of:
  - (f) placing the separated antibody in a fresh first solvent stream, the fresh first solvent stream being separated from a second solvent stream by an electrophoretic membrane having a molecular mass cut-off larger than that of the electrophoretic membrane used in step (b);
  - (g) selecting a pH of the fresh first solvent stream such that the pH is within 1 pH unit of the pI of the antibody;



(h) applying an electric potential between the two solvent streams causing movement of at least some of the contaminants through the membrane into the second solvent stream while the antibody is substantially retained in the fresh first solvent stream, or if entering the membrane, being substantially prevented from entering the second solvent stream;

(i) optionally, periodically stopping and reversing the electric potential to cause movement of any antibody having entered the membrane to move back into the fresh first solvent stream, wherein substantially not causing any contaminants that have entered the second solvent stream to re-enter the fresh first solvent stream; and

(j) repeating step (h) and optionally step (i) until the fresh first solvent stream contains the desired purity of antibody, wherein the recovery of the antibody is at least 70%.

5. The method according to claim 4 wherein the molecular mass cut-off of the electrophoretic membrane used in step (f) is at least 200 kDa.

6. The method according to claim 4 wherein the molecular mass cut-off of the electrophoretic membrane used in step (f) is 1000 kDa.

7. The method according to any one of claims 4 to 6 wherein the pH of the fresh first solvent stream in step (g) is from 6 to 8.

8. The method according any one of claims 4 to 6 wherein the pH of the fresh first solvent stream in step (g) is within 0.5 pH units of the pI of the antibody.

9. The method according to any one of claims 1 to 8 wherein recovery of the antibody is at least 90%.

10. A method of separating an antibody from a mixture of antibody and at least one contaminant, the method comprising:

(a) placing the antibody and contaminant mixture in a first solvent stream, the first solvent stream being separated from a second solvent stream by an electrophoretic membrane having a molecular mass cut-off of at least 200 kDa;

(b) selecting a pH of the first solvent stream such that the pH is within 1 pH unit of the pI of the antibody;

(c) applying an electric potential between the two solvent streams causing movement of at least some of the contaminants through the membrane into the second solvent stream while the antibody is substantially retained in the

first solvent stream, or if entering the membrane, being substantially prevented from entering the second solvent stream;

(d) optionally, periodically stopping and reversing the electric potential to cause movement of any antibody having entered the membrane to move back into the first solvent stream, wherein substantially not causing any contaminants that have entered the second solvent stream to re-enter the first solvent stream; and

(e) repeating step (c) and optionally step (d) until the first solvent stream contains the desired purity of antibody, wherein the recovery of the antibody is at least 70% and the antibody being less denatured or altered compared with the same antibody obtained by conventional antibody purification methods.

11. The method according to claim 10 wherein the antibody and contaminant mixture is a monoclonal antibody in ascitic fluid.

12. The method according to claim 10 or 11 wherein the molecular mass cut-off of the electrophoretic membrane used in step (a) is 1000 kDa.

13. The method according to any one of claims 10 to 12 wherein the pH of the first solvent stream in step (b) is from 6 to 8.

14. The method according to any one of claims 10 to 12 wherein the pH of the first solvent stream in step (b) is within 0.5 pH units of the pI of the antibody.

15. The method according to any one of claims 10 to 14 wherein recovery of the antibody is at least 90%.

16. An isolated antibody purified by the method according to any one of claims 1 to 15.

17. The isolated antibody according to claim 16 being a monoclonal antibody.

mj

**PCT**

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07K 1/26</b>		<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/62937</b>
			<b>(43) International Publication Date:</b> 9 December 1999 (09.12.99)
<b>(21) International Application Number:</b> PCT/AU99/00424 <b>(22) International Filing Date:</b> 2 June 1999 (02.06.99) <b>(30) Priority Data:</b> PP 3855      2 June 1998 (02.06.98)      AU <b>(71) Applicant (for all designated States except US):</b> GRADIPORE LIMITED [AU/AU]; Riverside Corporate Park, 35-105 Delhi Road, North Ryde, NSW 2113 (AU). <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> RYLATT, Dennis, Brian [AU/AU]; 10 Stuart Street, Ryde, NSW 2112 (AU). <b>(74) Agent:</b> F.B. RICE & CO.; 605 Darling Street, Balmain, NSW 2041 (AU).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>	

**(54) Title:** PURIFICATION OF ANTIBODIES

**(57) Abstract**

A method of separation of an antibody from a mixture of the antibody and at least one contaminant, the method comprising: a) placing the antibody and contaminant mixture in a first solvent stream, the first solvent stream being separated from a second solvent stream by an electrophoretic membrane; b) selecting the pH for the first solvent stream such that contaminants with an isoelectric point (pI) lower than the antibody to be separated will be charged; c) applying an electric potential between the two solvent streams causing movement of at least some of the contaminants through the membrane into the second solvent stream while the antibody is substantially retained in the first solvent stream, or if entering the membrane, being substantially prevented from entering the second solvent stream; d) optionally, periodically stopping and reversing the electric potential to cause movement of any antibody having entered the membrane to move back into the first solvent stream, wherein substantially not causing any contaminants that have entered the second solvent stream to re-enter first solvent stream; and e) repeating step c) and optionally step d) until the first solvent stream contains the desired purity of antibody.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakistan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## Purification of Antibodies

### Technical Field

The present invention relates to methods suitable for purification of antibodies, particularly monoclonal antibodies from ascites fluid.

### 5 Background Art

The processing of complex biological solutions is a major bottleneck in the biotechnology industry and there is a strong demand for cost effective technologies for the purification of naturally occurring and recombinant proteins. This is particularly true for antibodies including monoclonal  
10 antibodies, where there has been an on-going search for simple generic methods of purification. In particular, monoclonal antibodies have had an increasing number of research, therapeutic and diagnostic applications since their initial production in 1975. The difficulties in bioprocessing have meant that recoveries of monoclonal antibodies in existing purification schemes are  
15 rarely reported but are often in the range of 10 to 70%. Although new processes have become increasingly effective in terms of yield and recovery, commonly used processes often utilise harsh pH or ionic strength conditions for elution which may not always be compatible with maintaining maximal biological activity of antibodies.

20 The present inventor has found that preparative electrophoresis using Gradiflow technology (AU 601040) is particularly suitable for the purification of antibodies. In contrast to conventional methods, Gradiflow uses mild, non-denaturing buffers and conditions which may be utilised to produce more active antibody preparations.

### 25 Disclosure of Invention

In a first aspect, the present invention consists in a method of separation of an antibody from a mixture of the antibody and at least one contaminant, the method comprising:

- (a) placing the antibody and contaminant mixture in a first solvent stream,  
30 the first solvent stream being separated from a second solvent stream by an electrophoretic membrane;
- (b) selecting a pH for the first solvent stream such that contaminants with an isoelectric point (pI) lower than the antibody to be separated will be charged;
- 35 (c) applying an electric potential between the two solvent streams causing movement of at least some of the contaminants through the membrane into

the second solvent stream while the antibody is substantially retained in the first solvent stream, or if entering the membrane, being substantially prevented from entering the second solvent stream;

- 5 (d) optionally, periodically stopping and reversing the electric potential to cause movement of any antibody having entered the membrane to move back into the first solvent stream, wherein substantially not causing any contaminants that have entered the second solvent stream to re-enter first solvent stream; and
- 10 (e) repeating step (c) and optionally step (d) until the first solvent stream contains the desired purity of antibody.

Preferably, the antibody and contaminant mixture is a monoclonal antibody in ascitic fluid.

In a preferred embodiment of the first aspect of the present invention, the electrophoretic membrane has a molecular mass cut-off of about 50 to 150 kDa, preferably about 100 kDa. The *pI* of the antibody to be separated is usually obtained by isoelectric focusing (IEF). The pH of the first solvent stream is preferably about 7.5 to 9.5. Major protein contaminants, including albumin whose *pI* is well known to be 4.9, can be separated from the antibodies by being caused to transfer into the second solvent stream at pH 8.3.

20 In a second aspect, the present invention consists in a method of separation of an antibody from a mixture of the antibody and at least one contaminant, the method comprising:

- 25 (a) placing the separated antibody in a first solvent stream, the first solvent stream being separated from a second solvent stream by an electrophoretic membrane;
- (b) selecting a pH of the first solvent stream such that the pH is within 1 pH unit of the *pI* of the antibody;
- 30 (c) applying an electric potential between the two solvent streams causing movement of at least some of the contaminants through the membrane into the second solvent stream while the antibody is substantially retained in the first solvent stream, or if entering the membrane, being substantially prevented from entering the second solvent stream;
- 35 (d) optionally, periodically stopping and reversing the electric potential to cause movement of any antibody having entered the membrane to move back into the first solvent stream, wherein substantially not causing any

contaminants that have entered the second solvent stream to re-enter first solvent stream; and

(e) repeating step (c) and optionally step (d) until the first solvent stream contains the desired purity of antibody.

5       The electrophoretic membrane in step (a) preferably has a molecular mass cut-off at least about 200 kDa to ensure the contaminants can pass through to the second solvent stream. A cartridge containing a large 1000 kDa pore size separating-membrane has been found to be particularly suitable for this aspect of the present invention. The pH in step (b) is  
10 typically from about 6 to 8.0. It will be appreciated that the pH of the buffer will depend on the *pI* of the antibody to be purified and the *pIs* of the contaminants.

      The pH of the buffer used in step (b) can be above or below the *pI* of the antibody to be separated. Preferably, the pH is within 0.5 pH units of the  
15 *pI* of the antibody.

      In a third aspect, the present invention consists in a method of separation of an antibody from a mixture of the antibody and at least one contaminant, the method comprising:

20 (a - e) separating the antibody according to the first aspect of the present invention;

(f) placing the separated antibody in a fresh first solvent stream, the first solvent stream being separated from a second solvent stream by an electrophoretic membrane;

25 (g) selecting a pH of the fresh first solvent stream such that the pH is within 1 pH unit of the *pI* of the antibody;

(h) applying an electric potential between the two solvent streams causing movement of at least some of the contaminants through the membrane into the second solvent stream while the antibody is substantially retained in the fresh first solvent stream, or if entering the membrane, being substantially  
30 prevented from entering the second solvent stream;

(i) optionally, periodically stopping and reversing the electric potential to cause movement of any antibody having entered the membrane to move back into the fresh first solvent stream, wherein substantially not causing any contaminants that have entered the second solvent stream to re-enter first  
35 solvent stream; and

(j) repeating step (h) and optionally step (i) until the fresh first solvent stream contains the desired purity of antibody.

The molecular mass cut-off of the electrophoretic membrane used in step (f) is preferably larger than the membrane used in step (b). The electrophoretic membrane in step (f) preferably has a molecular mass cut-off at least about 200 kDa to ensure the contaminants can pass through to the second solvent stream. A cartridge containing a large 1000 kDa pore size separating-membrane has been found to be particularly suitable for this aspect of the present invention. The pH in step (g) is typically from about 6 to 8.0. It will be appreciated that the pH of the buffer will depend on the pI of the antibody to be purified and the pIs of the contaminants.

The pH of the buffer used in step (g) can be above or below the pI of the antibody to be separated. Preferably, the pH is within 0.5 pH units of the pI of the antibody.

The present inventor has been able to obtain percent recoveries of monoclonal antibodies from ascitic fluid of at least 70% and often greater than 90% using the methods according to the present invention.

In a fourth aspect, the present invention consists in use of Gradiflow in the purification and/or separation of antibodies.

In a fifth aspect, the present invention consists in an antibody purified by the method according to the first, second or third aspects of the present invention.

Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

In order that the present invention may be more clearly understood, preferred forms will be described in the following examples with reference to the accompanying drawings.

#### Brief Description of Drawings

Figure 1 shows the operating modes of the Gradiflow separating cartridge. (a) Sized-based separation - this is a first step in which major contaminants are removed downstream from antibody mixture upstream. (b) Charge-based separation - this is a second step suitable to remove any residual contaminants if requiring antibodies of higher purity.



Figure 2 shows SDS-PAGE of the purification of antibody 4. Lane 1 is upstream at 0 min, lanes 2-5 upstream after 10, 20, 30, and 40 min, respectively. Lane 6-9 show downstream at 10, 20, 30, and 40 min, respectively. Lane 10 contains SDS molecular mass markers.

Mab=monoclonal antibodies; kDa=Kilodaltons.

Figure 3 shows SDS-PAGE of the purified monoclonal antibodies according to the second aspect of the present invention. Lane 1 and 7 are the SDS-PAGE molecular weight markers. For contrast, the starting material for antibody 1 was placed in lane 2 while lanes 3, 4, 5 and 6 contain the final four product antibodies.

#### Modes for Carrying Out the Invention

#### EXPERIMENTAL

##### Antibodies

The antibodies used in this study were all generated by conventional procedures (Bundesen et al 1985) and supplied to Gradipore Limited by Agen Biomedical Brisbane, Australia as murine ascitic fluids. Table I contains the properties of the target monoclonal antibodies.

Table 1. Monoclonal antibodies (recovery as determined by EIA)

Antibody	Isotype	pI	Recovery	
			%	mg/ml antibody
1	IgG1	pH 7.3-7.5	94 <sup>a</sup>	8.9
2	IgG2a	pH 6.7-7.7	73 <sup>b</sup>	8.1
3	IgG2b	pH 6.6-6.9	79 <sup>b</sup>	10.8
4	IgG1	pH 6.8-7.0	71 <sup>b</sup>	10.0

<sup>a</sup> - denotes one step purification

<sup>b</sup> - denotes a two-step purification

##### Gradiflow technology

The separating cartridge of the Gradiflow contains a set of polyacrylamide-based restriction and separating membranes to enable the separation of macromolecules on the basis of size and/or charge (see Figure 1). A range of cartridges is available with  $M_r$  cut-offs ranging from 25,000 to 1,000,000. The ability to fractionate proteins over a range of pH and the use

of membranes of different pore sizes enables any target protein to be separated by virtue of its size or isoelectric point.

The Model LM1000 ( Gradipore Limited, Sydney, Australia) contains peristaltic pumps, peltier coolers and power supply. It is controlled by a personal computer under a Windows 95 and Lab View format. Alternatively, a manually configured instrument is also available which can operate with conventional peristaltic pumps and power supply (Margolis et al 1995; Corthals et al 1996; Horvath et al 1996; Corthals et al 1997).

### **Modes of separation**

#### *Size-based separation (Figure 1a)*

For size separation, a pH is selected at which all proteins have the same charge, in this case negative. Hence all of the proteins from the mixture circulating in the "upstream" compartment will try to migrate into the "downstream" compartment. If a membrane of restrictive pore size is selected, for example the  $M_r$  100,000 used in this case, molecules larger than  $M_r$  100,000 (such as the target antibodies) will be unable to transfer across the membrane and remain upstream. As essentially all proteins in mouse ascitic fluid have pI values less than pH 7.7, pH 8.3 was selected for size preparation in this paper. Under these conditions most of the ascitic proteins are transferred "downstream" leaving behind the  $M_r$  160 000 antibody molecules.

#### *Charged based separation (Figure 1b)*

For charge-based separation, a pH is selected between the isoelectric points of two proteins such that one protein will have a positive charge and the other a negative charge. In this example, the protein mixture continuously circulates in the "upstream" compartment. When the current is applied, the negatively charged protein migrates through the membrane to the "downstream" compartment. Continuous circulation of the upstream and downstream compartments allows complete separation of the two proteins.

The vast majority of non-antibody proteins in murine ascitic fluid have isoelectric points below pH 6.5 so that at a pH above pH 6.5, these proteins are negatively charged and will migrate downstream leaving behind the antibody which normally has a pI above pH 6.6. For charge separations, a membrane with a large pore size is usually employed ( $M_r$   $1 \times 10^6$ ) to allow for maximum transport across the membrane.

### Purification of monoclonal antibodies

Each sample of ascitic fluid (0.5 - 2 ml) was diluted with at least three volumes of a buffer containing 40 mM Tris-borate, 1 mM EDTA pH 8.3.

Firstly a size separation of each sample was carried out in this buffer for 30 to 40 min at 200 V with a  $M_r$  cut-off 100,000 separating membrane. Under these conditions, albumin and other impurities rapidly migrated across the membrane leaving behind the purified antibody upstream.

For higher purity, a second run was selected at a pH close to the  $pI$  of each specific antibody using a  $M_r$  cut-off  $1 \times 10^6$  membrane. For example 40 mM Tris buffer can be adjusted to the required pH with acetic acid. The run time was 40 min at 200 V. The remaining impurities migrated through the membrane while the antibody remained upstream. By taking 50  $\mu$ l aliquots of upstream and downstream at 10-min intervals during the first and second run, the purity of the target antibodies was then determined by denaturing sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The percent recovery was determined by enzyme immunoassay (ELA) after the runs were completed.

The upstream and downstream were harvested after 40 min. For maximum recovery of antibody, a small amount (7 ml) of running buffer was pumped in the upstream and downstream for a minute at the end of the separation process with the current reversed. After the current reversal was switched off, the upstream and downstream were allowed to circulate for another minute before the upstream wash was harvested and combined with the initial antibody harvested. An additional 10-15% of antibody can be recovered in this washing process

### Isoelectric focusing

The  $pI$  of each antibody was determined by running an isoelectric focusing (IEF) gel using a Novex (San Diego CA, USA) IEF gel apparatus as described by the manufacturer. Briefly, the running conditions involved a run time of 1 h at 100 V 1 h at 200 V and 500 V for 30 min. The IEF gel was fixed with a solution of 12% (w/v) trichloroacetic acid (Sigma Product No T8657) with 3.5% (w/v) 5-sulfosalicylic acid (Sigma Product No S-3147) in deionised water for 30 min before staining with Gradipure™ Coomassie Blue.

**Determination of antibody purity**

Samples were analysed by SDS-PAGE on Gradipore 4-20% T SDS gels [T=(g acrylamide + g *N,N'*-methylenebisacrylamide)/100 ml solution]. The changes to sample purity with time were determined by comparing the protein bands upstream and downstream at different times.

**Determination of antibody recovery***Protein concentration*

Protein levels in the upstream and downstream were determined by measuring the ultraviolet absorption at 280 nm. A 1 mg/ml solution of mouse monoclonal antibodies was assumed to have an absorbance of 1.2 AU.

*Enzyme immunoassay*

The antibody activity was determined by a two-site EIA using either antigen or unlabelled sheep anti-mouse immunoglobulin as the capturing component. The microplate was first coated with either 50 µl of antigen (10 µl/ml) or rabbit anti-mouse immunoglobulins (10 µl/ml) Dako (Carpinteria, USA) in phosphate-buffered saline (PBS) pH 7.4 for 1 h at room temperature.

Excess antigen was removed by inverting and tapping the plate and the plate was washed three times with PBS containing 0.1% Tween 20 (PBS/T). Next, 50 µl of a suitable dilution in PBS/T of the monoclonal fraction under test was added and the incubation was allowed to proceed for an hour at room temperature. After removal of unbound antibody by washing, bound antibody was labelled by the addition of a 1/1000 dilution of horseradish peroxidase (HRPO)-labelled anti anti-mouse antibody and incubated for another hour. Finally, the bound enzyme detected after further washing by the addition of substrate and stop solutions.

**RESULTS AND DISCUSSION****Isoelectric focusing**

IEF is a technique that enables proteins to be characterised by their *pI* values which can be used to determine the best conditions for a charge based separation. An IEF gel of the starting material showed that each ascitic fluid had a unique IEF pattern with the major difference being the position of the multiple bands of target antibodies.

The IEF gel indicated a range of *pI* values from 6.6 to 7.7 for the four different antibodies derived from ascitic fluid samples. The *pI* values of the antibodies are listed in Table 1. The variety of isoforms provides plausible reason for the low recoveries from conventional ion-exchange protocols for

antibodies as the charge heterogeneity could cause multiple broad peaks and tailing effects.

### **Purification of mouse antibodies**

#### *Size separation*

5           Size exclusion was chosen as the first step when IEF (Figure 1) revealed a wide variation in the isoelectric charge of individual antibodies. A membrane with a  $M_r$  cut-off of 100,000 was selected as this pore size should retain the  $M_r$  160,000 antibody, yet allow the rapid passage of smaller protein molecules. A pH of 8.3 was chosen so that the majority of immune ascitic  
10       fluid proteins had net negative charges at this pH.

          A time course for the purification of antibody 4 is depicted in Figure 2. Similar results were obtained for the other three antibodies. After 20 min, the most significant bands in the sample stream are the characteristic heavy and light chains of the monoclonal antibody. Acceptable purity was  
15       achieved after 30 min (lane 5 in Figure 2) without substantial improvement at 40 min. Lower-molecular-mass proteins with the most abundant being mouse serum albumin, rapidly passed through the  $M_r$  100,000 membrane leaving behind the antibody upstream. The downstream was harvested every  
20       10 min and showed decreasing amounts of protein in each subsequent harvest (Figure 2, lanes 7-9 ). Most of the impurities were removed from the antibody in the first 10 min (lane 7) with large amounts of albumin present in the two initial downstream harvests that were collected at 10 min and 20 min. Albumin had disappeared from the upstream after 10 min. This ending was interpreted, as residual albumin found downstream in the 10-min sample  
25       being in transit within the separation membrane when the 10-min sample was taken.

          These conditions were chosen for initial separation with a view to try to select a universal first step that would allow the purification of any antibody in good yield with the high degree of purity. The Tris-borate buffer  
30       was selected because it has proven to be a useful buffer for separations under native conditions in many other applications. The voltage was selected on the basis of the required speed of the separation with the aim of completing the process in less than 30 min. For most applications, the higher the voltage the more rapid the purification.

Some antibodies are thought to be labile at room temperature and there are many reports that temperature can affect protein folding with lower temperatures increasing protein volatility.

#### *Charge separation*

5 A higher degree of purity for each antibody can be achieved in a charged-based second step carried out at a pH near the  $pI$  of each antibody. As the isoelectric points vary, this meant a different pH was selected for each antibody. During the separations using either size or charge, there was no evidence that the solubility of each target antibody was affected by a pH  
10 higher than its  $pI$  or near its  $pI$ . The solubility of the proteins remained excellent with these operating conditions and choice of buffers used. Each different antibody solution was adjusted with acetic acid to the pH that was close to the  $pI$  prior to a charge separation. The membrane used for the charge separation was a  $M_r$   $1 \times 10^6$  pore size to increase the speed of removal  
15 of the contaminating proteins. Under these conditions, the monoclonal antibody now uncharged, remained upstream and the contaminating negatively charged proteins migrated downstream SDS-PAGE (Figure 3) indicated that a high degree of purity was achieved for all antibodies using this second step. The relatively high  $pI$  of antibody 1 allowed this antibody  
20 to be purified in a single step at pH 8.3 using  $M_r$   $1 \times 10^6$  pore size membrane (instead of  $M_r$  100,000). This antibody was expected to migrate through the  $M_r$   $1 \times 10^6$  membrane because it did have a small negative charge at this pH but for short runs of less than an hour, it remained upstream. Indeed with longer separation times (1-2 h) some migration downstream was noted.

#### 25 **Recovery**

The recovery of the monoclonal antibodies was determined by comparing the final biological activity of the antibody present upstream, downstream and in the washes with the starting material (Table I ). Although recoveries for antibodies 2, 3 and 4 (using two-stage purifications)  
30 were less than for antibody 1 (Table 1) quantities of >8 mg of each antibody were recovered per ml of ascitic fluid. This recovery was higher than the expected yields for other purification procedures. These higher activities recovered may be due to a combination of the mild buffers used the relatively short distance required for separation to occur with the separation cartridge  
35 and the short purification times.

The protocol developed takes the advantage of the large size ( $M_r$  160,000) of the monoclonal antibodies relative to other proteins in ascitic fluid and their relatively high  $pI$  values compared to other proteins in murine ascitic fluid. The protocol described here is less complex than conventional chromatographic purification techniques where more variables need to be considered. The immunoglobulin fraction is usually about 2-25% of the total protein in ascitic fluids. The high content of lipid present in ascitic fluid is known to reduce the life of fractionation columns. In the present experiments, excellent purification and recovery without the need to delipidise or pretreat the samples was achieved.

Initially, small amounts (10-20 mg) of each target antibody were purified to test the invention. Linear scale up from the 15 cm<sup>2</sup> membranes (used here) to 200 cm<sup>2</sup> has been accomplished by the present inventor and co-workers previously for haemoglobin/albumin separations (Horvath et al 1994). Preliminary scale up from 2 ml to 10 ml of mouse ascites fluid on the 15 cm<sup>2</sup> cartridges was achieved. Longer processing time or a larger separation cartridges may be required for larger quantities of proteins.

Comparison of antibodies separated according to the present invention with the same antibodies purified by standard techniques including Protein-A, Protein-G and ion exchange chromatography by a collaborating third party revealed the antibodies obtained by the present invention were more active. Furthermore, the yields of antibodies were greater using the present invention. Tables 2 and 3 show the results of the comparisons of several purifications of antibodies.

Table 2. Yield of Mouse IgG1 monoclonal antibody

Purification Method	Yield (mg antibody recovered)
Protein-A	65
Invention	68
Ion exchange	60

Table 3. Yield of Rat IgG2b monoclonal antibody

Purification Method	Yield (%)
Protein-G	83
Invention	91
Ion exchange	81

5 Electrophoretic analysis (SDS-PAGE) of antibodies purified by the present invention revealed lower number of protein bands indicating that the present method does not cleave or damage the antibodies compared with other purification techniques. Not only can the present invention provide greater yields of antibody, the invention also provides more active and less denatured antibody preparations.

10 It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.



## REFERENCES

PG Bundesen, DM Wyatt, LE Cottis, AS Blake, DA Massingham, WA Fletcher,  
G Street, JS Welch, DB Rylatt *Vet Immunol Immunopath* 8 (1985) 245-260.

5

Horvath ZC, Corthals GL, Wrigley CW and Margolis J. Multifunctional  
apparatus for electrokinetic processing of proteins. *Electrophoresis* 1994 15  
968-971.

10

Margolis J, Corthals G and Horvath ZS. Preparative reflux electrophoresis.  
*Electrophoresis* 1995 16 98-100.

15

Corthals GL, Margolis J, Williams KL and Gooley AA. The role of pH and  
membrane porosity in preparative electrophoresis. *Electrophoresis* 1996 17  
771-775.

20

Horvath ZC, Gooley AA, Wrigley CW, Margolis J and Williams KL.  
Preparative affinity membrane electrophoresis. *Electrophoresis* 1996 17 224-  
226.

Corthals GL, Molloy MP, Herbert BR, Williams KL and Gooley AA.  
Prefractionation of protein samples prior to two-dimensional electrophoresis.  
*Electrophoresis* 1997 18 317-323.

## CLAIMS:

1. A method of separation of an antibody from a mixture of the antibody and at least one contaminant, the method comprising:
  - (a) placing the antibody and contaminant mixture in a first solvent stream, the first solvent stream being separated from a second solvent stream by an electrophoretic membrane;
  - (b) selecting a pH for the first solvent stream such that contaminants with an isoelectric point (pI) lower than the antibody to be separated will be charged;
  - (c) applying an electric potential between the two solvent streams causing movement of at least some of the contaminants through the membrane into the second solvent stream while the antibody is substantially retained in the first solvent stream, or if entering the membrane, being substantially prevented from entering the second solvent stream;
  - (d) optionally, periodically stopping and reversing the electric potential to cause movement of any antibody having entered the membrane to move back into the first solvent stream, wherein substantially not causing any contaminants that have entered the second solvent stream to re-enter first solvent stream; and
  - (e) repeating step (c) and optionally step (d) until the first solvent stream contains the desired purity of antibody.
2. The method according to claim 1 wherein the antibody and contaminant mixture is a monoclonal antibody in ascitic fluid.
3. The method according to claim 1 or 2 wherein the electrophoretic membrane has a molecular mass cut-off of 50 to 150 kDa.
4. The method according to claim 3 wherein the electrophoretic membrane has a molecular mass cut-off of 100 kDa.
5. The method according to any one of claims 1 to 4 wherein the pH of the first solvent stream is 7.5 to 9.5.
6. The method according to any one of claims 1 to 5 further including the steps of:
  - (f) placing the separated antibody in a fresh first solvent stream, the first solvent stream being separated from a second solvent stream by an electrophoretic membrane;
  - (g) selecting a pH of the fresh first solvent stream such that the pH is within 1 pH unit of the pI of the antibody;

- (h) applying an electric potential between the two solvent streams causing movement of at least some of the contaminants through the membrane into the second solvent stream while the antibody is substantially retained in the fresh first solvent stream, or if entering the membrane, being substantially prevented from entering the second solvent stream;
- (i) optionally, periodically stopping and reversing the electric potential to cause movement of any antibody having entered the membrane to move back into the fresh first solvent stream, wherein substantially not causing any contaminants that have entered the second solvent stream to re-enter fresh first solvent stream; and
- (j) repeating step (h) and optionally step (i) until the fresh first solvent stream contains the desired purity of antibody.
7. The method according to claim 6 wherein the molecular mass cut-off of the membrane used in step (f) is larger than that used in step (b).
8. The method according to claim 7 wherein the molecular mass cut-off of the electrophoretic membrane used in step (f) is at least 200 kDa.
9. The method according to claim 8 wherein the molecular mass cut-off of the electrophoretic membrane used in step (f) is 1000 kDa.
10. The method according to any one of claims 6 to 9 wherein the pH in step (g) is from 6 to 8.
11. The method according any one of claims 6 to 9 wherein the pH in step (g) is within 0.5 pH units of the *pI* of the antibody.
12. The method according to any one of claims 1 to 11 wherein percent recovery of the antibody is at least 70%.
13. The method according to claim 12 wherein percent recovery of the antibody is at least 90%.
14. A method of separation of an antibody from a mixture of the antibody and at least one contaminant, the method comprising:
- (a) placing the separated antibody in a first solvent stream, the first solvent stream being separated from a second solvent stream by an electrophoretic membrane;
- (b) selecting a pH of the first solvent stream such that the pH is within 1 pH unit of the *pI* of the antibody;
- (c) applying an electric potential between the two solvent streams causing movement of at least some of the contaminants through the membrane into the second solvent stream while the antibody is substantially retained in the

first solvent stream, or if entering the membrane, being substantially prevented from entering the second solvent stream;

(d) optionally, periodically stopping and reversing the electric potential to cause movement of any antibody having entered the membrane to move back into the first solvent stream, wherein substantially not causing any contaminants that have entered the second solvent stream to re-enter first solvent stream; and

(e) repeating step (c) and optionally step (d) until the first solvent stream contains the desired purity of antibody.

10 15. The method according to claim 14 wherein the antibody and contaminant mixture is a monoclonal antibody in ascitic fluid.

16. The method according to claim 14 or 15 wherein the molecular mass cut-off of the electrophoretic membrane used in step (a) is at least 200 kDa.

15 17. The method according to claim 16 wherein the molecular mass cut-off of the electrophoretic membrane used in step (a) is 1000 kDa.

18. The method according to any one of claims 14 to 17 wherein the pH in step (b) is from 6 to 8.

19. The method according to any one of claims 14 to 17 wherein the pH in step (b) is within 0.5 pH units of the pI of the antibody.

20 20. An antibody purified by the method according to any one of claims 1 to 19.

21. The antibody according to claim 20 being a monoclonal antibody.




Figure 1




Figure 2





Figure 3

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU 99/00424

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>												
Int Cl <sup>6</sup> : C07K 1/26												
According to International Patent Classification (IPC) or to both national classification and IPC												
<b>B. FIELDS SEARCHED</b>												
Minimum documentation searched (classification system followed by classification symbols)												
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched												
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) See Separate Sheet												
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>												
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.										
P,X	Journal of Chromatography A, 827 (1998) 329-335 "Purification of monoclonal antibodies from ascitic fluid using preparative electrophoresis"; S Lim et al	1-21										
X Y	Electrophoresis, (1994), Vol.15 (7), pages 968-971 "Multifunctional apparatus for electrokinetic processing of proteins"; Z. Stephen Horvath et al	1-21 1, 6, 14										
Y	Electrophoresis, (1995), Vol.16 (1), pages 98-100 "Preparative reflux electrophoresis"; Joel Margolis et al	1, 6, 14										
<input type="checkbox"/> Further documents are listed in the continuation of Box C <input type="checkbox"/> See patent family annex												
<p>* Special categories of cited documents:</p> <table border="0"> <tr> <td>"A" document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"E" earlier application or patent but published on or after the international filing date</td> <td>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O" document referring to an oral disclosure, use, exhibition or other means</td> <td>"&amp;" document member of the same patent family</td> </tr> <tr> <td>"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family	"P" document published prior to the international filing date but later than the priority date claimed	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention											
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone											
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art											
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family											
"P" document published prior to the international filing date but later than the priority date claimed												
Date of the actual completion of the international search 28 June 1999		Date of mailing of the international search report 05 JUL 1999										
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200 WODEN ACT 2606 AUSTRALIA Facsimile No.: (02) 6285 3929		Authorized officer  IAN DOWD Telephone No.: (02) 6283 2273										



INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU 99/00424

**Box B**

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN: File WPIDS. Keywords: (antibod? and (purif? or separat?) and (electrophor? or isoelectric)  
File CA. Keywords: (antibod? and (purif? or separat?) and electrophor? and isoelectric and ascit?)  
File MEDLINE. Keywords: (antibod? and (purif? or separat?) and electrophor? and isoelectric and ascit?)

ORBIT: File WPAT. Search terms

1. C07K 1/14 and antibod: and electrophor:
2. C07K 3/14 and antibod:
3. C07K 1/26.